145 related articles for article (PubMed ID: 17604501)
21. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
McCubrey JA; Steelman LS; Franklin RA; Abrams SL; Chappell WH; Wong EW; Lehmann BD; Terrian DM; Basecke J; Stivala F; Libra M; Evangelisti C; Martelli AM
Adv Enzyme Regul; 2007; 47():64-103. PubMed ID: 17382374
[No Abstract] [Full Text] [Related]
22. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
Russo P; Loprevite M; Cesario A; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
[TBL] [Abstract][Full Text] [Related]
23. Farnesyl Transferase Inhibitors as Potential Anticancer Agents.
Bagchi S; Rathee P; Jayaprakash V; Banerjee S
Mini Rev Med Chem; 2018; 18(19):1611-1623. PubMed ID: 30068272
[TBL] [Abstract][Full Text] [Related]
24. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathways: BCR-ABL.
Cilloni D; Saglio G
Clin Cancer Res; 2012 Feb; 18(4):930-7. PubMed ID: 22156549
[TBL] [Abstract][Full Text] [Related]
26. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
27. Targeting oncogenic Ras signaling in hematologic malignancies.
Ward AF; Braun BS; Shannon KM
Blood; 2012 Oct; 120(17):3397-406. PubMed ID: 22898602
[TBL] [Abstract][Full Text] [Related]
28. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
Zhang M; Jiang D
Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
[TBL] [Abstract][Full Text] [Related]
29. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
O'Regan RM; Khuri FR
Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
[TBL] [Abstract][Full Text] [Related]
30. Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents.
Minutolo F; Asso V; Bertini S; Betti L; Ciriaco M; Danesi R; Gervasi G; Ghilardi E; Giovanetti E; Giannaccini G; Placanica G; Prota G; Rapposelli S; Macchia M
Med Chem; 2005 May; 1(3):239-44. PubMed ID: 16787319
[TBL] [Abstract][Full Text] [Related]
31. RAS and leukemia: from basic mechanisms to gene-directed therapy.
Beaupre DM; Kurzrock R
J Clin Oncol; 1999 Mar; 17(3):1071-9. PubMed ID: 10071302
[TBL] [Abstract][Full Text] [Related]
32. Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway.
Li Y; Sun Y; Fan L; Zhang F; Meng J; Han J; Guo X; Zhang D; Zhang R; Yue Z; Mei Q
Biochem Pharmacol; 2014 Mar; 88(2):150-7. PubMed ID: 24462916
[TBL] [Abstract][Full Text] [Related]
33. [The design of muti-target antitumor drugs affecting on FTase and Raf-1 kinase].
Zhao J; Zhu YJ; Zeng L; Wang Q; Jiang FC
Yao Xue Xue Bao; 2011 Feb; 46(2):170-8. PubMed ID: 21542288
[TBL] [Abstract][Full Text] [Related]
34. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
35. Antroquinonol blocks Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells.
Ho CL; Wang JL; Lee CC; Cheng HY; Wen WC; Cheng HH; Chen MC
Biomed Pharmacother; 2014 Oct; 68(8):1007-14. PubMed ID: 25312820
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of the ras oncogene as therapeutic targets.
Ghobrial IM; Adjei AA
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
[TBL] [Abstract][Full Text] [Related]
37. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
40. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
